Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in patients with melanoma. We compared the efficacy and safety of pembrolizumab at doses of 2 mg/kg and 10 mg/kg every 3 weeks in patients with ipilimumab-refractory advanced melanoma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Sep 20 2014

Volume: 384

Issue: 9948

Affiliations

[1 ] Gustave Roussy and INSERM U981, Paris-Sud, France. Electronic address: caroline.robert@gustaveroussy.fr.

[2 ] University of California Los Angeles, Los Angeles, CA, USA.

[3 ] Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

[4 ] Dana-Farber Cancer Institute, Boston, MA, USA.

[5 ] Angeles Clinic and Research Institute, Los Angeles, CA, USA.

[6 ] Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Westmead, NSW, Australia; University of Sydney, Sydney, NSW, Australia.

[7 ] H Lee Moffitt Cancer Center, Tampa, FL, USA.

[8 ] Princess Margaret Cancer Centre, Toronto, ON, Canada.

[9 ] University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[10 ] Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.

[11 ] South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.

[12 ] Mayo Clinic, Rochester, MN, USA.

[13 ] University of Pittsburgh, Pittsburgh, PA, USA.

[14 ] Mayo Clinic, Jacksonville, FL, USA.

[15 ] Gustave Roussy and INSERM U981, Paris-Sud, France.

[16 ] Merck, Whitehouse Station, NJ, USA.

[17 ] University of California San Francisco, San Francisco, CA, USA.

Article

Publisher Item ID: S0140-6736(14)60958-2

DOI: 10.1016/S0140-6736(14)60958-2

PubMed ID: 25034862

SO-VID: aa018b13-2349-4209-882f-5259c52e5e1b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 640

See all cited by

- Version 1